Nephrologist @PennGlomCTR @PennKidney | Glomerular Diseases & Onconephrology | views mine
Philadelphia, PA
Joined January 2018
- Tweets1K
- Following2.1K
- Followers2.3K
- Likes3.6K
Pinned Tweet
Please join me in welcoming @PennGlomCTR to #NephTwitter — a part of @PennKidney offering comprehensive care to patients with #glomerular diseases, and opportunities to participate in clinical trials of novel therapies. – at Philadelphia, PA
Ralph Nader, MD, FASN retweeted
The 2026 Penn Medicine Glomerular Disease Conference was held today
- in both live and virtual format. Great presentations and discussions! #GlomerularDisease #Nephrology @PennKidney
Ralph Nader, MD, FASN retweeted
📣NEW Editorial:
High-cost glomerular disease drugs: eagerly anticipated with caveats
🆓doi.org/10.1093/ndt/gfaf261
Ralph Nader, MD, FASN retweeted
Congratulations to everyone in the fellowship match! We are thrilled to welcome these wonderful physicians to the @PennKidney family for #Nephrology #Fellowship in 2026!
Ralph Nader, MD, FASN retweeted
Complement-
Kidney biopsy is grossly inadequate when it comes to complement: we stain for only C3/C1q!
LMD/MS can:
-determine complement pathways
-determine burden of complement
-Activated vs entrapped complement
-Assess complement regulating proteins
journals.lww.com/cjasn/abstr…
Ralph Nader, MD, FASN retweeted
Now online in @NDTsocial
Nephrotoxicity of Non-Platinum Agents and Miscellaneous Nephrotoxic Drugs
🧐Knowing these kidney toxicity profiles is critical to maximize the oncologic benefit while preserving kidney function.
▶️academic.oup.com/ndt/article…
Ralph Nader, MD, FASN retweeted
The PARASOL Project is expanding its focus to include biomarkers and endpoints in APOL1 kidney disease and primary membranous nephropathy in addition to FSGS. Learn more and get involved: eu1.hubs.ly/H0nr8Lv0 @Tobias_B_Huber @BradRovin @ph_nachman @MiKTMC @Dr_KeishaGibson @DrRulanParekh @ASmith_Stats @UPennDBEI
Ralph Nader, MD, FASN retweeted
#Corticosteroid Effects in #IgA Nephropathy by Baseline #Proteinuria and Estimated #GFR
#VisualAbstract by @DrPallaviPrasad
kireports.org/article/S2468-…
Ralph Nader, MD, FASN retweeted
Great win for AUB Med!🚀🎉A record-breaking 85% match rate in #Match2025—the highest in 8 years! With 122 applicants and 104 matches, both hitting all-time highs, our grads are proving that excellence knows no limits! The future of medicine is brighter than ever! 🔥👩⚕️👨⚕️
Ralph Nader, MD, FASN retweeted
#WhyScience Today, I am launching a 100-day Twitter/X campaign highlighting the importance of science, academia, and academic research in the U.S., with one tweet per day. Please help to increase visibility by liking, retweeting and adding to it.
Ralph Nader, MD, FASN retweeted
Cardiovascular and Kidney Outcomes of Non-Diabetic CKD by Albuminuria Severity: Findings From the @CRICStudy
bit.ly/434CTeO
@shulman_rachel @CohenS26072691 @PeterPReese1 @jordy_bc @PennKidney @PennMedicine #VisualAbstract
Ralph Nader, MD, FASN retweeted
In the Literature by @ClaraFischman and Lawrence B. Holzman:
Identification of Nephrin Autoantibodies Signals New Chapter for Glomerular Disease
bit.ly/3XMpvI6 (FREE)
@PennMedicine
Original article in @NEJM ⬇️
Original Article: Autoantibodies Targeting Nephrin in Podocytopathies nej.md/3UU5o9u
Science behind the Study: Kidney Disease and Antinephrin Antibodies nej.md/4fnl1zD
#Nephrology
ALT Diagram of the disruption of slit diaphragm by antinephrin autoantibodies
Ralph Nader, MD, FASN retweeted
Our Yearly #Glomerular
Disease Fellows Workshop with #fellows from all over the region coming to learn about glomerular diseases!
#Nephrology @PennKidney
Ralph Nader, MD, FASN retweeted
Antibody-mediated podocytopathies: a disease entity that implies immunotherapy
🆓doi.org/10.1093/ndt/gfae166
📸A proposed diagnostic algorithm in patients with nephrotic syndrome and suspected podocytopathy
Ralph Nader, MD, FASN retweeted
🎇Our new paper in @ScienceMagazine: Kidney Multiome-Based Genetic Scorecard Reveals Convergent Coding and Regulatory Variants.
@Hongbo919Liu
science.org/doi/10.1126/scie…
1. Full spectrum of genetic variants related to kidney function (1,000 loci). 2. Comprehensive annotation of discovered genetic variants using 32 new omics datasets and tools (QTLs, single cell data), uncovering 600+ genes for kidney function. 3. 161 genes previously believed to contribute only to rare monogenic diseases, which harbor common variants affecting CKD in the general population. 4. Discovered a large number of new druggable targets for kidney disease. 5. Developed a Kidney Genetics Scorecard for integration and interpretation
Ralph Nader, MD, FASN retweeted
🚨 Breaking down the REGENCY trial 🚨
A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
Ralph Nader, MD, FASN retweeted
Presented at #ISNWCN:
In the REGENCY trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results: nej.md/3Eq6gxV
ALT The subgroup analysis of complete renal response at week 76 in the intention-to-treat population.
Ralph Nader, MD, FASN retweeted
Now open access in @NDTsocial
Obinutuzumab for the management of immune-mediated glomerular diseases
🧐Obinutuzumab holds significant potential as a novel first-line therapeutic option for various immune-mediated glomerular diseases
▶️academic.oup.com/ndt/article…
Ralph Nader, MD, FASN retweeted
De novo Membranous Nephropathy in Renal Allografts is Associated With #Protocadherin FAT1
doi.org/10.1016/j.ekir.2024.…
#KIRResearchLetter #MembranousNephropathy
Ralph Nader, MD, FASN retweeted
Identification of two distinct clusters in membranous lupus nephritis patients: recognition of a high-risk profile based on unsupervised analysis
doi.org/10.1093/ndt/gfae295
